Skip to main content

Glyburide Side Effects

Medically reviewed by Last updated on Jul 22, 2023.

Applies to glyburide: oral tablet.

Serious side effects of Glyburide

Along with its needed effects, glyburide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking glyburide:

Less common


Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking glyburide:

Symptoms of overdose

Other side effects of Glyburide

Some side effects of glyburide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to glyburide: compounding powder, oral tablet.


Like all sulfonylureas, this drug may commonly cause hypoglycemia and in some case it may be severe. Proper patient selection, dose, and patient instructions are important to avoid hypoglycemic episodes.[Ref]



Very rare (less than 0.01%): Disulfiram-like reaction

Frequency not reported: Hypoglycemia, hyponatremia, weight gain, lactic acidosis, syndrome of inappropriate antidiuretic hormone (SIADH) secretion


Frequency not reported: Hepatic porphyria

Neonatal Diabetes:

Very common (10% or more): Hypoglycemia[Ref]


Adverse gastrointestinal effects occur in about 1% to 2% of patients and appear to be dose related; they may subside following a dose reduction. Pancreatitis has been reported rarely.[Ref]

Common (1% to 10%): Nausea, vomiting, epigastric fullness or sensation of pressure, abdominal pain, anorexia, dyspepsia, diarrhea, heartburn

Rare (less than 0.1%): Pancreatitis

Neonatal Diabetes:

Very common (10% or more): Transitory diarrhea, abdominal pain, vomiting, dyspepsia

Common (1% to 10%): Tooth discoloration[Ref]


Very rare (less than 0.01%): Allergic vasculitis

Frequency not reported: Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, angioedema, arthralgia, myalgia, vasculitis, erythema multiforme, erythema nodosum, bullous eruptions, exfoliative dermatitis, photosensitivity, Stevens-Johnson syndrome[Ref]

Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5 % of patients during clinical trials. In some cases these were transient and disappeared despite continue therapy. Hypersensitivity reactions affecting the skin usually occur within the first 6 weeks of treatment with a sulfonylurea.[Ref]



Common (1% to 10%): Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions

Frequency not reported: Alopecia/hypotrichoses, increased sweating, facial edema, angioedema, bullous reactions, erythema multiforme, exfoliative dermatitis


-Frequency not reported: Porphyria cutanea tarda, photosensitivity reactions[Ref]

Allergic skin reactions including pruritus, erythema, urticaria, morbilliform, erythematous and maculopapular and bullous skin eruptions or psoriasiform drug eruptions occurred in 1.5 % of patients during clinical trials. These may be transient and may disappear despite continued therapy. Bullous reactions, erythema multiforme, and exfoliative dermatitis have been reported. If skin reactions persist, this drug should be discontinued.[Ref]


Changes in accommodation and/or blurred vision are thought to be related to fluctuations in glucose levels.[Ref]

Frequency not reported: Changes in accommodation and/or blurred vision, diplopia, visual disturbances, blindness[Ref]



Postmarketing reports: Hemolytic anemia


Frequency not reported: Leukopenia, agranulocytosis, thrombocytopenia, thrombocytopenia purpura, eosinophilia, bone marrow aplasia, coagulation disorders, hemolytic anemia, aplastic anemia, anemia, pancytopenia[Ref]



Rare (less than 0.1%): Cholestatic jaundice, hepatitis

Frequency not reported: Liver function abnormalities including isolated transaminase elevations

Postmarketing reports:


Frequency not reported: Increased liver enzymes (AST, ALT), abnormal liver function, cholestasis, cholestatic hepatitis, granulomatous hepatitis, bilirubinemia

Neonatal Diabetes:

Very common (10% or more): Transient increased transaminases[Ref]


Frequency not reported: Abnormal renal function, acute renal failure[Ref]


Frequency not reported: Arthralgia, arthritis[Ref]

Nervous system

Frequency not reported: Paresthesia, tremor, convulsions, encephalopathy, confusion, headache, cerebrovascular disorders[Ref]


Frequency not reported: Deafness, fever[Ref]


Frequency not reported: Acute psychosis[Ref]


1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. Glynase PresTab (glyburide). Pfizer U.S. Pharmaceuticals Group. 2015.

3. Product Information. Diabeta (glyburide). Hoechst Marion-Roussel Inc, Kansas City, MO.

4. Product Information. Micronase (glyburide). Pharmacia and Upjohn. 2002;PROD.

5. Cerner Multum, Inc. UK Summary of Product Characteristics.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.